Skip to content

Arvinas ARVN Enterprise value

Enterprise value at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$1.63B+45.1%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$6.74B+280%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$1.2B+381%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$163.63M-76.9%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$958.05M+65.4%
Immunome logo
ImmunomeIMNM
$1.9B+470%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Calculated from Arvinas’s reported figures.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's enterprise value?
Arvinas (ARVN) reported enterprise value of $599.29M in Q1 2026.
How has Arvinas's enterprise value changed year-over-year?
Arvinas's enterprise value increased by 45.3% year-over-year, from $412.48M to $599.29M.
What is the long-term trend for Arvinas's enterprise value?
Over 5 years (2020 to 2025), Arvinas's enterprise value has grown at a -30.6% compound annual growth rate (CAGR), from $3.91B to $627.9M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.